InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,728.80
(
0.00%
)
US TECH 100
19,524.40
(
0.14%
)
Dow Jones
42,052.19
(
0.00%
)
Brent Oil
74.86
(
1.06%
)
Bitcoin
68,741.80
(
0.00%
)
Post# of 66
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Shizane

Send PM Follow Ignore
Followers 1
Posts 87
Boards Moderated 1
Alias Born 08/14/2013

Shizane

Re: None

Wednesday, 09/11/2013 8:56:33 AM

Wednesday, September 11, 2013 8:56:33 AM

Post# of 66
NEWS: NVAX - Currently Holding (updated)

These presentations reflect our progress in defining the importance of the palivizumab-like antibody and confirm that the RSV F vaccine induces promising immune responses in the elderly population.


These two studies are important because they demonstrate the potential of our vaccine candidate to prevent a major public health problem in the elderly and also provide protection to infants through passive maternal immunization. These are critical unmet needs which we plan to address in later-stage efficacy studies.


>Gregory Glenn, M.D., Senior Vice President and Chief Medical Officer of Novavax


ICAAC Presentations Highlight Potential Protective Effects of Novavax’ RSV Vaccine Candidate


Presentations:
RSV F Protein Vaccine is Well-Tolerated and Immunogenic in Elders

Passive Immunization with RSV F Vaccine-Induced Polyclonal Antibodies Protect Cotton Rats From RSV A Challenge

SHIZANE





*Above statements are wholly my opinion (unless stated otherwise) and should be a taken as such

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up